Fibrous membranes in diabetic retinopathy and bevacizumab

Retina

Volumn 30, Issue 7, 2010, Pages 1012-1016

  Pattwell, David M ^a   Stappler, Theodor ^a   Sheridan, Carl ^a   Heimann, Heinrich ^a   Gibran, Syed K ^a   Wong, David ^a,b   Hiscott, Paul ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD31 ANTIGEN; CD34 ANTIGEN; COLLAGEN; SMOOTH MUSCLE ACTIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETES CONTROL; DIABETIC RETINOPATHY; DRUG EFFECT; ENDOTHELIUM CELL; EPIRETINAL MEMBRANE; FEMALE; FIBROBLAST; GLIA CELL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; LENS; MALE; MICROSCOPY; PROGNOSIS; RETINA BLOOD VESSEL; RETINA DETACHMENT; RETINA NEOVASCULARIZATION; RETROSPECTIVE STUDY; STROMA; VITRECTOMY; VITREOUS HEMORRHAGE;

ACTINS; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; ANTIGENS, CD34; BASEMENT MEMBRANE; DIABETIC RETINOPATHY; FEMALE; FIBROSIS; HUMANS; IMMUNOENZYME TECHNIQUES; INJECTIONS; MALE; MIDDLE AGED; RETINAL NEOVASCULARIZATION; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 77954730897     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181cb463a     Document Type: Article

References (22)

1. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
2. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695-1715.
3. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006;26:1006-1013.
4. Arevalo JF, Maia M, Flynn H Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe diabetic retinopathy. Br J Ophthalmol 2008;92:213-216.
5. Arevalo JF, Wu L, Sanchez JG, et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye (Lond) 2009;23:117-123.
6. Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye (Lond) 2009;23: 108-111.
7. Mason JO III, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:685-688.
8. Minnella AM, Savastano CM, Ziccardi L, Scupola A, Falsini B, Balestrazzi E. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Ophthalmol 2008;86:683-687.
9. Ruiz-Moreno JM, Montero JA, Lugo F, Amat P, Staicu C. Intravitreal bevacizumab in recurrent diabetic vitreous haemorrhage after vitrectomy. Acta Ophthalmol 2008;86:231-232.
10. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-278.
11. Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU, Jorge R. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008;86: 385-389.
12. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004;7:335-345.
13. Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006;26:512-518.
14. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008;246:837-842.
15. Hiscott P, Gray R, Grierson I, Gregor Z. Cytokeratincontaining cells in proliferative diabetic retinopathy membranes. Br J Ophthalmol 1994;78:219-222.
16. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52.
17. Verheul HM, Lolkema MP, Qian DZ, et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 2007;13: 5341-5347.
18. Warner TD. Relationships between the endothelin and nitric oxide pathways. Clin Exp Pharmacol Physiol 1999;26:247-252.
19. Okuda Y, Tsurumaru K, Suzuki S, et al. Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells. Life Sci 1998;63:477-484.
20. Uhlmann S, Friedrichs U, EichlerW, Hoffmann S,Wiedemann P. Direct measurement of VEGF-induced nitric oxide production by choroidal endothelial cells. Microvasc Res 2001;62:179-189.
21. Soliman W, Vinten M, Sander B, et al. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Acta Ophthalmol 2008;86:365-371.
22. Gibran SK, Sachdev A, Stappler T, Newsome R, Wong D, Hiscott P. Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab therapy (bevacizumab). Br J Ophthalmol 2007;91:602-604.